This Article Full Text Full Text (PDF) Purchase Article View Shopping Cart Alert me when this article is cited Alert me if a correction is posted Services Email this article to a colleague Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Save to my personal folders Download to citation manager Rights & Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Sauerbrei, W. Articles by Schumacher, M. Search for Related Content PubMed PubMed Citation Articles by Sauerbrei, W. Articles by Schumacher, M. Social Bookmarking                            What's this?

Randomized 2 x 2 Trial Evaluating Hormonal Treatment and the Duration of Chemotherapy in Node-Positive Breast Cancer Patients: An Update Based on 10 Years’ Follow-Up

From the Institute of Medical Biometry and Medical Informatics, University of Freiburg, Freiburg; Department of Gynaecology, University of Heidelberg, Heidelberg; Department of Chemical Oncology, University of Duesseldorf, Duesseldorf; Department of Gynaecology, Kreiskrankenhaus, Kronach; and Department of Gynaecology, Marienhospital Essen-Altenessen, Essen, Germany.

Address reprint requests to W. Sauerbrei, PhD, Institute of Medical Biometry and Medical Informatics, University of Freiburg, Stefan-Meier-Str.26, D-79104 Freiburg, Germany; email wfs{at}imbi uni- freiburg.de.

PURPOSE: In 1984, the German Breast Cancer Study Group started a multicenter randomized trial to compare six versus three cycles of cyclophosphamide, methotrexate, and fluorouracil (CMF) starting perioperatively and to investigate the additional effect of tamoxifen as adjuvant treatment in node-positive breast cancer patients treated with mastectomy.

PATIENTS AND METHODS: From 1984 to 1989, 473 patients were randomized from 41 institutions. After a median follow-up of approximately 10 years for overall survival (OS) and 9 years for event-free survival (EFS), the treatment groups were compared with respect to OS and EFS. Results based on a median follow-up of 56 months have been published earlier.

RESULTS: Estimated cumulative locoregional incidence rate after 10 years was 19.9%; the corresponding rate of distant recurrences was 41.3%. Concerning duration of chemotherapy, we did not find any difference between six and three cycles of CMF (EFS: relative risk [RR] in multivariate analysis = 0.95; 95% confidence interval [CI], 0.74 to 1.21 OS: RR = 0.90; 95% CI, = 0.69 to 1.18). Treatment with tamoxifen resulted in an improvement in outcome (EFS: RR = 0.81; 95% CI, 0.61 to 1.07, OS: RR = 0.74; 95% CI, 0.55 to 1.0) although it proved not significant. Number of positive lymph nodes and progesterone receptor were the dominant prognostic factors.

CONCLUSION: In this study, we observed some tendency in favor of hormonal treatment, which is in agreement with the literature. Concerning duration of chemotherapy, the results of this study provide further evidence that a reduction to three cycles of CMF is possible without increasing the risk of recurrence or death. For a definitive conclusion, however, further investigations are required.

Sponsored by the Bundesministerium für Forschung und Technologie and by the Deutsche Forschungsgemeinschaft.

CiteULike    Complore    Connotea    Del.icio.us    Digg    Facebook    Reddit    Technorati    Twitter    What's this?

This article has been cited by other articles:

				C. Schmoor, A. Caputo, and M. Schumacher Evidence from Nonrandomized Studies: A Case Study on the Estimation of Causal Effects Am. J. Epidemiol., May 1, 2008; 167(9): 1120 - 1129. [Abstract] [Full Text] [PDF]

				P. Therasse, L. Mauriac, M. Welnicka-Jaskiewicz, P. Bruning, T. Cufer, H. Bonnefoi, E. Tomiak, K. I. Pritchard, A. Hamilton, and M.J. Piccart Final Results of a Randomized Phase III Trial Comparing Cyclophosphamide, Epirubicin, and Fluorouracil With a Dose-Intensified Epirubicin and Cyclophosphamide + Filgrastim as Neoadjuvant Treatment in Locally Advanced Breast Cancer: An EORTC-NCIC-SAKK Multicenter Study J. Clin. Oncol., March 1, 2003; 21(5): 843 - 850. [Abstract] [Full Text] [PDF]

				P. Fumoleau, P. Kerbrat, P. Romestaing, P. Fargeot, A. Bremond, M. Namer, S. Schraub, M.-J. Goudier, J. Mihura, A. Monnier, et al. Randomized Trial Comparing Six Versus Three Cycles of Epirubicin-Based Adjuvant Chemotherapy in Premenopausal, Node-Positive Breast Cancer Patients: 10-Year Follow-Up Results of the French Adjuvant Study Group 01 Trial J. Clin. Oncol., January 15, 2003; 21(2): 298 - 305. [Abstract] [Full Text] [PDF]

				A. C. Wolff and M. D. Abeloff Adjuvant Chemotherapy for Postmenopausal Lymph Node-Negative Breast Cancer: It Ain't Necessarily So J Natl Cancer Inst, July 17, 2002; 94(14): 1041 - 1043. [Full Text] [PDF]

				International Breast Cancer Study Group (IBCSG) Endocrine Responsiveness and Tailoring Adjuvant Therapy for Postmenopausal Lymph Node-Negative Breast Cancer: A Randomized Trial J Natl Cancer Inst, July 17, 2002; 94(14): 1054 - 1065. [Abstract] [Full Text] [PDF]

				M. J Piccart, C. Lohrisch, L. Duchateau, and M. Buyse Taxanes in the Adjuvant Treatment of Breast Cancer: Why Not Yet? J Natl Cancer Inst Monographs, December 1, 2001; 2001(30): 88 - 95. [Abstract] [Full Text] [PDF]